Applications of Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation

September 10, 2023 updated by: Jianqiang Tang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Applications of Near-infrared Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation: A Prospective Randomized Controlled Study

To investigate the accuracy of fluorescence angiography technique IMA classification and the impact of lymph node mapping technique on the dissection of No. 253 lymph nodes.

Study Overview

Detailed Description

Multiple studies, including randomized controlled trials (RCTs), have demonstrated that lymph node imaging techniques can effectively increase the number of harvested lymph nodes in gastric and colorectal cancer surgeries . However, there remains a scarcity of research specifically focused on the surgical procedure of fluorescent-guided clearance of No. 253 lymph nodes. Most existing studies have been retrospective analyses, and the need for prospective studies is evident. Further clinical research is crucial to explore the successful application of fluorescence lymph node imaging combined with indocyanine green (ICG) fluorescence angiography and its multifunctional fusion. To address this gap, investigators plan to conduct a randomized controlled trial comparing the outcomes between the use of ICG Fluorescence lymph node Imaging combined with Fluorescence angiography (FIFA group) and conventional techniques (non-ICG group) in laparoscopic rectal cancer surgery. Specifically, investigators focus will be on the preservation of the left colic artery (LCA) and the clearance of No. 253 lymph nodes. The primary objectives of our study are to simplify surgical procedures, enhance surgical safety, and provide substantial evidence for the further promotion and adoption of this technique.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100021
        • Recruiting
        • Cancer Hospital Chinese Academy of Medical Sciences
        • Contact:
        • Principal Investigator:
          • Jianqiang Tang, Dr.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients aged between 18 and 75 years
  • Colonoscopic biopsy confirmed colorectal adenocarcinoma
  • The tumor was located in the rectum or upper rectum, and the surgical method was Dxion
  • No local complications before operation (no obstruction, incomplete obstruction, no massive active bleeding, no perforation, abscess formation, no local invasion)
  • Preoperative imaging diagnosis was cT1-4aNxM0
  • The hematopoietic functions of heart, lung, liver, kidney and bone marrow meet the requirements of surgery and anesthesia
  • Sign the informed consent form

Exclusion Criteria:

  • Previous surgical history of malignant colorectal tumors
  • The surgical methods were combined abdominoperineal resection, Hartman operation and ISR operation
  • There are contraindication of laparoscopic surgery, such as severe cardiopulmonary insufficiency
  • Patients who have undergone multiple abdominal and pelvic surgeries or extensive abdominal adhesion
  • Patients with intestinal obstruction, intestinal perforation, intestinal bleeding and other emergency operations
  • ASA grade ≥IV and/or ECOG physical status score ≥2 points
  • Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases can not tolerate surgery
  • Have a history of serious mental illness
  • Patients with uncontrolled infection before operation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Laparoscopic No. 253 lymph node dissection and preserving the LCA under fluorescence guidance.
Preoperatively, indoycine green fluorescent dye was injected into the anus to trace the No. 253 lymph nodes, and intraoperatively, arterial branching of the mesentery was performed by intravenous injection of fluorescent dye to preserve the left colic artery.
Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
Active Comparator: Performing laparoscopic No. 253 lymph node dissection and preserving the LCA.
Conventional laparoscopic approach for dissection of the No. 253 lymph nodes and preservation of the left colic artery.
Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
success rate of IMA fluorescence imaging
Time Frame: From the beginning to the end of the surgery.
ICG solution was prepared at a concentration of 2.5 g/L. A dose of 0.05 mg-0.10 mg/kg body weight of ICG was administered intravenously through a peripheral or central vein. Before the injection of ICG, the fluorescence laparoscope was set to the original fluorescence mode to monitor the IMA region in real-time.Record the success or failure rate of IMA fluorescence imaging in the observation group. Classify the successful IMA fluorescence imaging results into four different types according to the Morro classification and calculate the proportion of each type in successful imaging.
From the beginning to the end of the surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Left colic artery retention rate
Time Frame: From the beginning to the end of the surgery.
Recording whether the left colic artery is preserved during surger.
From the beginning to the end of the surgery.
Incidence of IMA bleeding events
Time Frame: From the beginning to the end of the surgery.
Document incidents of mesenteric artery or vein bleeding caused by vascular injury during surgery.
From the beginning to the end of the surgery.
No.253 lymph node dissection time
Time Frame: From the beginning to the end of the surgery.
Measured based on surgical videos.
From the beginning to the end of the surgery.
Operation time
Time Frame: From the beginning to the end of the surgery.
Data obtained from anesthesia records.
From the beginning to the end of the surgery.
Intraoperative blood loss
Time Frame: From the beginning to the end of the surgery.
Data obtained from anesthesia records.
From the beginning to the end of the surgery.
Protective ostomy rate
Time Frame: From the beginning to the end of the surgery.
Data obtained from surgical records.
From the beginning to the end of the surgery.
Complication rate within 30 days after operation
Time Frame: within 30 days after operation.
According to the Clavien-Dindo classification system, complications were categorized into five grades. The postoperative status of each patient was recorded within 30 days, and the proportion of complications in each grade was calculated as a percentage of the total number of observations.
within 30 days after operation.
Assessment of postoperative anal function urinary function within 30 days
Time Frame: Assessment conducted once before surgery, on postoperative day 7, and on postoperative day 30.
Evaluation of Low Anterior Resection Syndrome (LARS) scale, assessed using the following scales at preoperative, postoperative day 7, and day 30. Scores range from 0 to 42, with lower scores indicating better outcomes.
Assessment conducted once before surgery, on postoperative day 7, and on postoperative day 30.
Measurement of residual urine volume in the bladder.
Time Frame: On the day the catheter was removed after surgery.
Bladder residual urine volume was measured on the same day as catheter removal. A bladder residual urine volume of less than 50 ml was considered indicative of good bladder function, while a volume greater than or equal to 50 ml was considered indicative of urinary retention.
On the day the catheter was removed after surgery.
Arterial development time
Time Frame: From the beginning to the end of the surgery.
Measured based on surgical videos.
From the beginning to the end of the surgery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2023

Primary Completion (Estimated)

May 1, 2024

Study Completion (Estimated)

May 1, 2024

Study Registration Dates

First Submitted

August 23, 2023

First Submitted That Met QC Criteria

September 10, 2023

First Posted (Actual)

September 13, 2023

Study Record Updates

Last Update Posted (Actual)

September 13, 2023

Last Update Submitted That Met QC Criteria

September 10, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCC-4123

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe